Deerfield Management Company, L.P. (Series C) Autolus Therapeutics PLC Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AUTL
# of Institutions
104Shares Held
163MCall Options Held
2.8KPut Options Held
13.4K-
Wellington Management Group LLP Boston, MA24.2MShares$55.5 Million0.02% of portfolio
-
Blackstone Inc New York, NY20.5MShares$46.9 Million0.35% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X018.6MShares$42.5 Million83.42% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$35 Million2.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$28.3 Million0.67% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $208M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...